Full Press Release Details
CARLSBAD, Calif.,Nov. 7, 2011/PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) today announced its financial results for the quarter endedSeptember 30, 2011. The Company finished the third quarter of 2011 with a pro forma net operating loss (NOL) of$20.0 millionand$44.9 millionfor the three and nine months endedSeptember 30, 2011, respectively, compared to a pro forma NOL of$6.0 millionand$23.1 millionfor the same periods in 2010. The Company finished the third quarter of 2011 with nearly$365 millionin cash.
"Our most notable success this year has been the submission of the Kynamro™ marketing authorization application to the European Medicines Agency. With this submission, we are one step closer to commercializing Kynamro for patients who are at great risk of dying from their cardiovascular disease. Genzyme remains on track to submit the U.S. application for marketing approval in the fourth quarter and is actively preparing to launch Kynamro next year in the U.S. and Europe. Kynamro represents the first major commercial opportunity for Isis, and we are looking forward to its potential launch next year," saidB. Lynne Parshall, J.D., Chief Operating Officer, Chief Financial Officer and Secretary of Isis. "Together with Genzyme, we are initiating our next Kynamro study, FOCUS FH, this year, which is intended to support an expansion of the market for Kynamro for severe forms of hypercholesterolemia. We and Genzyme are committed to continuing investments in this novel medicine to make it available to as many patients as appropriate to treat their severe and fatal cardiovascular disease."
Upcoming Key Milestones
• File for marketing approval for Kynamro™ (mipomersen) inthe United Statesin the fourth quarter of 2011 for patients with homozygous Familial Hypercholesterolemia (FH).
• Initiate 12 month clinical study, titled 'evaluating the saFety and atherOgeniC lipoprotein redUction of mipomerSen in FH (FOCUS FH)', to support additional indications inthe United StatesandEurope, and an alternative dosing regimen.
• Report Phase 1 data on ISIS-FXIRx, ISIS-TTRRx, ISIS-SGLT2Rx and ISIS-APOCIIIRx.
Financial Results
On a GAAP basis, Isis reported a loss from operations of$22.3 millionand$52.5 millionfor the three and nine months endedSeptember 30, 2011, respectively, compared to$8.9 millionand$32.5 millionfor the same periods in 2010.
All pro forma amounts referred to in this press release exclude non-cash stock compensation. Please refer to the reconciliation of pro forma and GAAP measures, which is provided later in this release.
Revenue
Revenue for the three and nine months endedSeptember 30, 2011was$20.7 millionand$66.7 million, respectively, compared to$28.6 millionand$82.1 millionfor the same periods in 2010. Isis' revenue fluctuates based on the nature and timing of payments under agreements with the Company's partners, including license fees, milestone-related payments and other payments. For example, revenue in the first nine months of 2011 included more revenue from GlaxoSmithKline (GSK) compared to 2010 due to the timing of the amortization of the upfront fee from GSK, which began in the second quarter of 2010. This increase in revenue was offset by less revenue from Bristol-Myers Squibb and no revenue from Alnylam Pharmaceuticals compared to the same period in 2010 because the amortization of upfront fees ended in 2010.
As Isis' drugs advance in development, Isis earns milestone payments, but the timing of these payments fluctuates. For instance, in the first nine months in 2010, Isis recognized as revenue$13 millionfor milestone payments compared to approximately$6 millionin milestone payments in the first nine months of 2011. Since the end of the third quarter, Isis has earned an additional$5 millionmilestone payment from GSK for designating ISIS-AATRx as a development candidate. Because Isis achieved this milestone in October, the Company will recognize revenue from the milestone payment in the fourth quarter of 2011.
Operating Expenses
On a pro forma basis, operating expenses for the three and nine months endedSeptember 30, 2011were$40.7 millionand$111.6 million, respectively, compared to$34.6 millionand$105.1 millionfor the same periods in 2010. Isis' operating expenses in the first nine months of 2011 reflected moderately higher costs associated with Isis' maturing pipeline of drugs as these drugs move forward to more advanced stages of development, including into larger, longer clinical studies. While Isis' share of mipomersen development expenses will be shared equally with Genzyme in 2012, many of the drugs in Isis' pipeline will enter later-stage clinical development. Therefore, Isis expects the Company's operating expenses to be moderately higher next year.
On a GAAP basis, Isis' operating expenses for the three and nine months endedSeptember 30, 2011were$43.0 millionand$119.2 million, respectively, compared to$37.6 millionand$114.6 millionfor the same periods in 2010.
Net Loss
Isis reported a net loss of$26.9 millionand$64.8 millionfor the three and nine months endedSeptember 30, 2011, respectively, compared to$12.5 millionand$47.3 millionfor the same periods in 2010. Basic and diluted net loss per share for the three and nine months endedSeptember 30, 2011was$0.27per share and$0.65per share, respectively, compared to$0.13per share and$0.48per share for the same periods in 2010. In the first nine months of 2011 Isis' net loss increased compared to the same period in 2010 primarily due to a$20.0 millionincrease in Isis' net operating loss.
Balance Sheet
As ofSeptember 30, 2011, Isis had cash, cash equivalents and short-term investments of$364.8 millioncompared to$472.4 millionatDecember 31, 2010and had working capital of$293.5 millionatSeptember 30, 2011compared to$377.2 millionatDecember 31, 2010. The decrease in cash and working capital primarily relates to cash used to fund Isis' operations.
Isis' leases on its former research and development facilities expire at the end of 2011. Rather than invest in costly renovations to these facilities, the Company chose to consolidate the majority of its operations in a new leased facility that Biomed Realty Trust, Inc. (BMR) constructed. To make the Company's move, which happened inAugust 2011, as efficient as possible, Isis requested access to the new facility prior to the completion of construction. To gain early access, Isis agreed to modify its lease to accept additional responsibility. As a result, accounting rules required Isis to record the cost of the facility as a fixed asset with a corresponding liability. Isis is depreciating the building over its economic life and Isis' rent payments, which begin onJanuary 1, 2012, will decrease the liability over the term of the lease.
Business Highlights
"Marketing approval of Kynamro will be an important milestone for Isis. We are working with Genzyme to continue to enhance Kynamro's profile and market opportunity. Genzyme recently completed a Special Protocol Assessment, or SPA, with the FDA for the next Kynamro clinical study. The study, FOCUS FH, is designed to achieve three goals: support the expansion of the FH patient population to include severe heterozygous FH in the U.S., support an alternative dosing regimen of three times a week dosing, and support potentially broadening of the FH indication beyond severe inEurope. We and Genzyme are focused not only on the initial commercial opportunities for Kynamro but also on the longer-term commercial opportunities as we continue to develop this important product," continued Ms. Parshall.
"Although Kynamro is our flagship drug and will be the first systemic antisense drug to reach the market, our pipeline goes well beyond Kynamro. Numerous drugs in our pipeline have demonstrated efficacy in early clinical studies and could represent significant commercial opportunities," continued Ms. Parshall. "The success of our drug discovery and development efforts is evident every quarter as we move our drugs closer to the market. Already this year, we have initiated clinical studies on five drugs, reported encouraging data on our CRP drug and added new drugs into development to treat a wide variety of diseases. We anticipate continuing this steady progress for the rest of the year and into 2012.
"Our business strategy is successful as evidenced by the growth of our partnered pipeline and the substantial cash from our partnering deals. We benefit financially both in the near-term and long-term, from upfront fees, milestone payments, royalties and profit sharing payments and other types of commercial participation. This year, we have earned$13 millionin milestones and upfront payments from our partner, GSK, with the expansion of our collaboration to include a sixth target, initiation of clinical development on our TTR drug and identification of the next drug, ISIS-AATRx, to move into development. This collaboration provides us with a knowledgeable partner and allows us to quickly expand our severe and rare disease franchise," concluded Ms. Parshall.
Corporate and Drug Development Highlights
• Dr.John Kasteleinpresented data from the mipomersen open-label extension study at the European Society of Cardiology Congress 2011. These data, in patients who have been treated with mipomersen for greater than one year, demonstrated sustained reductions in all measured atherogenic lipids with a safety profile consistent with the Phase 3 studies.
• Genzyme reached an agreement with the FDA on the design of the FOCUS FH study via a Special Protocol Assessment (SPA).
• Isis initiated Phase 1 studies on ISIS-GCGRRx and ISIS-GCCRRx.
• Isis added a new drug candidate, ISIS-AATRx, to its pipeline in Isis' GSK collaboration. Isis earned a$5 millionmilestone payment.
• Isis and CHDI renewed their collaboration to discover and develop an antisense drug for the treatment of Huntington's Disease.
• Isis filed a patent infringement lawsuit against Santaris Pharma based upon Santaris' commercial activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies.
Conference Call
At4:30 p.m. Eastern Timetoday,November 7, Isis will conduct a live webcast conference call to discuss the earnings release and related activities. Interested parties my listen to the call by dialing 888-396-2384 and refer to passcode "ISIS 2011", or access the webcast atwww.isispharm.com. A webcast replay will be available for a limited time at the same address.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available atwww.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, the planned commercialization of mipomersen, and the therapeutic and commercial potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year endedDecember 31, 2010and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Kynamro™ is a trademark of Genzyme Corporation.
| Isis Pharmaceuticals, Inc.Selected Financial InformationCondensed Consolidated Statements of Operations(In Thousands, Except Per Share Data) | |||||||||
| Three months ended, | Nine months ended, | ||||||||
| September 30, | September 30, | ||||||||
| 2011 | 2010 | 2011 | 2010 | ||||||
| Revenue: | (unaudited) | (unaudited) | |||||||
| Research and development revenue under collaborative agreements | $20,189 | $27,785 | $64,508 | $77,484 | |||||
| Licensing and royalty revenue | 524 | 839 | 2,175 | 4,569 | |||||
| Total revenue | 20,713 | 28,624 | 66,683 | 82,053 | |||||
| Expenses: | |||||||||
| Research and development | 39,924 | 34,716 | 110,178 | 105,827 | |||||
| General and administrative | 3,105 | 2,855 | 8,989 | 8,724 | |||||
| Total operating expenses | 43,029 | 37,571 | 119,167 | 114,551 | |||||
| Loss from operations | (22,316) | (8,947) | (52,484) | (32,498) | |||||
| Other income (expense): | |||||||||
| Equity in net loss of Regulus Therapeutics Inc. | (386) | (930) | (2,275) | (6,358) | |||||
| Investment income | 575 | 776 | 1,896 | 2,590 | |||||
| Interest expense | (4,773) | (3,338) | (11,624) | (9,835) | |||||
| Gain (loss) on investments, net | 18 | (15) | (267) | (1,162) | |||||
| Loss before income tax expense | (26,882) | (12,454) | (64,754) | (47,263) | |||||
| Income tax expense | - | - | (11) | (2) | |||||
| Net loss | $(26,882) | $(12,454) | $(64,765) | $(47,265) | |||||
| Basic and diluted net loss per share | $(0.27) | $(0.13) | $(0.65) | $(0.48) | |||||
| Shares used in computing basic and diluted net loss per share | 99,687 | 99,196 | 99,620 | 99,101 | |||||
Isis Pharmaceuticals, Inc.
Selected Financial Information
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Data)
Three months ended,
Nine months ended,
September 30,
September 30,
2011
2010
2011
2010
Revenue:
(unaudited)
(unaudited)
Research and development revenue under collaborative agreements
$20,189
$27,785
$64,508
$77,484
Licensing and royalty revenue
524
839
2,175
4,569
Total revenue
20,713
28,624
66,683
82,053
Expenses:
Research and development
39,924
34,716
110,178
105,827
General and administrative
3,105
2,855
8,989
8,724
Total operating expenses
43,029
37,571
119,167
114,551
Loss from operations
(22,316)
(8,947)
(52,484)
(32,498)
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
(386)
(930)
(2,275)
(6,358)
Investment income
575
776
1,896
2,590
Interest expense
(4,773)
(3,338)
(11,624)
(9,835)
Gain (loss) on investments, net
18
(15)
(267)
(1,162)
Loss before income tax expense
(26,882)
(12,454)
(64,754)
(47,263)
Income tax expense
-
-
(11)
(2)
Net loss
$(26,882)
$(12,454)
$(64,765)
$(47,265)
Basic and diluted net loss per share
$(0.27)
$(0.13)
$(0.65)
$(0.48)
Shares used in computing basic and diluted net loss per share
99,687
99,196
99,620
99,101
| Isis Pharmaceuticals, Inc.Reconciliation of GAAP to Pro Forma Basis:Condensed Consolidated Operating Expenses and Loss From Operations(In Thousands) | |||||||||
| Three months ended,September 30, | Six months ended,September 30, | ||||||||
| 2011 | 2010 | 2011 | 2010 | ||||||
| (unaudited) | (unaudited) | ||||||||
| As reported operating expenses according to GAAP | $43,029 | $37,571 | $119,167 | $114,551 | |||||
| Excluding compensation expense related to stock options | (2,364) | (2,960) | (7,596) | (9,448) | |||||
| Pro forma operating expenses | $40,665 | $34,611 | $111,571 | $105,103 | |||||
| As reported loss from operations according to GAAP | $(22,316) | $(8,947) | $(52,484) | $(32,498) | |||||
| Excluding compensation expense related to stock options | (2,364) | (2,960) | (7,596) | (9,448) | |||||
| Pro forma loss from operations | $(19,952) | $(5,987) | $(44,888) | $(23,050) | |||||
Isis Pharmaceuticals, Inc.
Reconciliation of GAAP to Pro Forma Basis:
Condensed Consolidated Operating Expenses and Loss From Operations
(In Thousands)
Three months ended,
September 30,
Six months ended,
September 30,
2011
2010
2011
2010
(unaudited)
(unaudited)
As reported operating expenses according to GAAP
$43,029
$37,571
$119,167
$114,551
Excluding compensation expense related to stock options
(2,364)
(2,960)
(7,596)
(9,448)
Pro forma operating expenses
$40,665
$34,611
$111,571
$105,103
As reported loss from operations according to GAAP
$(22,316)
$(8,947)
$(52,484)
$(32,498)
Excluding compensation expense related to stock options
(2,364)
(2,960)
(7,596)
(9,448)
Pro forma loss from operations
$(19,952)
$(5,987)
$(44,888)
$(23,050)
Reconciliation of GAAP to Pro Forma Basis
As illustrated in the Selected Financial Information in this press release, pro forma operating expenses and pro forma loss from operations were adjusted from GAAP to exclude compensation expense related to stock options, which are non-cash. Isis has regularly reported non-GAAP measures for operating expenses and loss from operations as pro forma results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Isis reports these pro forma results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Isis' pro forma results is consistent with how Isis' management internally evaluates the performance of its operations.
| Isis Pharmaceuticals, Inc.Condensed Consolidated Balance Sheets(In Thousands) | |||||
| September 30, | December 31, | ||||
| 2011 | 2010 | ||||
| (unaudited) | |||||
| Assets: | |||||
| Cash, cash equivalents and short-term investments | $364,763 | $472,353 | |||
| Other current assets | 12,326 | 10,784 | |||
| Property, plant and equipment, net | 98,019 | 35,703 | |||
| Other assets | 30,677 | 31,637 | |||
| Total assets | $505,785 | $550,477 | |||
| Liabilities and stockholders' equity: | |||||
| Other current liabilities | $31,114 | $31,388 | |||
| Current portion of deferred contract revenue | 52,428 | 74,502 | |||
| 2 5/8% convertible subordinated notes | 139,239 | 132,895 | |||
| Long-term obligations, less current portion | 73,619 | 15,867 | |||
| Investment in Regulus Therapeutics Inc. | 3,145 | 870 | |||
| Long-term deferred contract revenue | 19,415 | 50,413 | |||
| Stockholders' equity | 186,825 | 244,542 | |||
| Total liabilities and stockholders' equity | $505,785 | $550,477 | |||
Isis Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(In Thousands)
September 30,
December 31,
2011
2010
(unaudited)
Assets:
Cash, cash equivalents and short-term investments
$364,763
$472,353
Other current assets
12,326
10,784
Property, plant and equipment, net
98,019
35,703
Other assets
30,677
31,637
Total assets
$505,785
$550,477
Liabilities and stockholders' equity:
Other current liabilities
$31,114
$31,388
Current portion of deferred contract revenue
52,428
74,502
2 5/8% convertible subordinated notes
139,239
132,895
Long-term obligations, less current portion
73,619
15,867
Investment in Regulus Therapeutics Inc.
3,145
870
Long-term deferred contract revenue
19,415
50,413
Stockholders' equity
186,825
244,542
Total liabilities and stockholders' equity
$505,785
$550,477